您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Cabergoline-d6
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Cabergoline-d6
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Cabergoline-d6图片
包装:1mg
规格:98%
市场价:17781元
分子量:457.6

产品介绍
A neuropeptide with diverse biological activities
货号:ajcx21960
CAS:N/A
分子式:C26H31D6N5O2
分子量:457.6
溶解度:Acetonitrile: Soluble,DMSO: Soluble
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Cabergoline-d6is intended for use as an internal standard for the quantification of cabergoline by GC- or LC-MS. Cabergoline is a dopamine D2receptor agonist (Ki= 0.912 nM in rat striatal homogenates).1It is selective for dopamine D2over D1receptors (Ki= 6,935 nM). Cabergoline inhibits prolactin secretion in, and growth of, isolated rat pituitary tumor cells in a concentration-dependent manner, an effect that can be blocked by the dopamine D2receptor antagonist haloperidol .2Cabergoline reduces phosphorylation of mammalian target of rapamycin (mTOR) and induces the formation of LC3 puncta, a marker of autophagy, and apoptosis in MMQ rat pituitary cells.3In vivo, cabergoline (0.25 mg/kg) stimulates motor activity and decreases dyskinesias in a cynomolgus monkey model of Parkinson's disease induced by MPTP.4Formulations containing cabergoline have been used in the treatment of prolactinomas.


1.Miyagi, M., Itoh, F., Taya, F., et al.Dopamine receptor affinities in vitro and stereotypic activities in vivo of cabergoline in ratsBiol. Pharm. Bull.19(9)1210-1213(1996) 2.Eguchi, K., Kawamoto, K., Uozumi, T., et al.Effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors: In vitro culture studiesEndocr. J.42(3)413-420(1995) 3.Lin, S.J., Leng, Z.G., Guo, Y.H., et al.Suppression of mTOR pathway and induction of autophagy-dependent cell death by cabergolineOncotarget6(36)39329-39341(2015) 4.Grondin, R., Goulet, M.T., Di Paolo, T., et al.Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primatesBrain Res.735(2)298-306(1996)